• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微小 RNA-204-5p:Xp11.2 易位性肾细胞癌的新型候选尿生物标志物。

MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.

机构信息

Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

出版信息

Cancer Sci. 2019 Jun;110(6):1897-1908. doi: 10.1111/cas.14026. Epub 2019 May 24.

DOI:10.1111/cas.14026
PMID:31006167
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6549932/
Abstract

Xp11.2 translocation renal cell carcinoma (Xp11 tRCC) is a rare sporadic pediatric kidney cancer caused by constitutively active TFE3 fusion proteins. Tumors in patients with Xp11 tRCC tend to recur and undergo frequent metastasis, in part due to lack of methods available to detect early-stage disease. Here we generated transgenic (Tg) mice overexpressing the human PRCC-TFE3 fusion gene in renal tubular epithelial cells, as an Xp11 tRCC mouse model. At 20 weeks of age, mice showed no histological abnormalities in kidney but by 40 weeks showed Xp11 tRCC development and related morphological and histological changes. MicroRNA (miR)-204-5p levels in urinary exosomes of 40-week-old Tg mice showing tRCC were significantly elevated compared with levels in control mice. MicroRNA-204-5p expression also significantly increased in primary renal cell carcinoma cell lines established both from Tg mouse tumors and from tumor tissue from 2 Xp11 tRCC patients. All of these lines secreted miR-204-5p-containing exosomes. Notably, we also observed increased miR-204-5p levels in urinary exosomes in 20-week-old renal PRCC-TFE3 Tg mice prior to tRCC development, and those levels were equivalent to those in 40-week-old Tg mice, suggesting that miR-204-5p increases follow expression of constitutively active TFE3 fusion proteins in renal tubular epithelial cells prior to overt tRCC development. Finally, we confirmed that miR-204-5p expression significantly increases in noncancerous human kidney cells after overexpression of a PRCC-TFE3 fusion gene. These findings suggest that miR-204-5p in urinary exosomes could be a useful biomarker for early diagnosis of patients with Xp11 tRCC.

摘要

Xp11.2 易位性肾细胞癌(Xp11 tRCC)是一种罕见的散发性小儿肾肿瘤,由组成性激活的 TFE3 融合蛋白引起。Xp11 tRCC 患者的肿瘤往往会复发并经常发生转移,部分原因是缺乏早期疾病检测方法。在这里,我们在肾小管上皮细胞中过表达人 PRCC-TFE3 融合基因,生成了 Xp11 tRCC 的转基因(Tg)小鼠模型。在 20 周龄时,小鼠肾脏没有组织学异常,但在 40 周龄时出现了 Xp11 tRCC 发展和相关的形态和组织学变化。与对照小鼠相比,显示出 tRCC 的 40 周龄 Tg 小鼠尿液外泌体中的 microRNA(miR)-204-5p 水平显著升高。从 Tg 小鼠肿瘤和 2 名 Xp11 tRCC 患者的肿瘤组织中建立的原发性肾细胞癌细胞系中,miR-204-5p 的表达也显著增加。所有这些细胞系都分泌含有 miR-204-5p 的外泌体。值得注意的是,我们还观察到在 tRCC 发展之前,20 周龄的肾脏 PRCC-TFE3 Tg 小鼠尿液外泌体中的 miR-204-5p 水平升高,并且这些水平与 40 周龄的 Tg 小鼠相当,表明 miR-204-5p 在明显的 tRCC 发展之前,在肾小管上皮细胞中表达组成性激活的 TFE3 融合蛋白后增加。最后,我们证实了在过表达 PRCC-TFE3 融合基因后,非癌性人肾细胞中的 miR-204-5p 表达显著增加。这些发现表明,尿液外泌体中的 miR-204-5p 可能是 Xp11 tRCC 患者早期诊断的有用生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03d/6549932/bde3f8c4fd2e/CAS-110-1897-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03d/6549932/f6a066e020e7/CAS-110-1897-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03d/6549932/aa0bb0034c4f/CAS-110-1897-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03d/6549932/2165da79ca98/CAS-110-1897-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03d/6549932/f4b7864b87ec/CAS-110-1897-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03d/6549932/bde3f8c4fd2e/CAS-110-1897-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03d/6549932/f6a066e020e7/CAS-110-1897-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03d/6549932/aa0bb0034c4f/CAS-110-1897-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03d/6549932/2165da79ca98/CAS-110-1897-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03d/6549932/f4b7864b87ec/CAS-110-1897-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d03d/6549932/bde3f8c4fd2e/CAS-110-1897-g005.jpg

相似文献

1
MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.微小 RNA-204-5p:Xp11.2 易位性肾细胞癌的新型候选尿生物标志物。
Cancer Sci. 2019 Jun;110(6):1897-1908. doi: 10.1111/cas.14026. Epub 2019 May 24.
2
Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.雄激素受体调控 TFE3 融合蛋白的 SUMOylation 和泛素化是 Xp11.2 易位肾细胞癌治疗的潜在靶点。
Clin Transl Med. 2022 Apr;12(4):e797. doi: 10.1002/ctm2.797.
3
PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma.PRCC-TFE3 融合介导的 PRKN/parkin 依赖性线粒体自噬促进 PRCC-TFE3 易位肾细胞癌中的细胞存活和增殖。
Autophagy. 2021 Sep;17(9):2475-2493. doi: 10.1080/15548627.2020.1831815. Epub 2020 Oct 21.
4
TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.TFE3 Xp11.2 易位肾细胞癌小鼠模型揭示了新的治疗靶点,并鉴定 GPNMB 为人类疾病的诊断标志物。
Mol Cancer Res. 2019 Aug;17(8):1613-1626. doi: 10.1158/1541-7786.MCR-18-1235. Epub 2019 May 1.
5
Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.Xp11易位性肾细胞癌的临床异质性:融合亚型、年龄和分期的影响
Mod Pathol. 2014 Jun;27(6):875-86. doi: 10.1038/modpathol.2013.208. Epub 2013 Dec 6.
6
NMRK2 is an efficient diagnostic indicator for Xp11.2 translocation renal cell carcinoma.NMRK2 是 Xp11.2 易位性肾细胞癌的有效诊断指标。
J Pathol. 2024 Oct;264(2):228-240. doi: 10.1002/path.6340. Epub 2024 Aug 2.
7
Estradiol increases risk of topoisomerase IIβ-mediated DNA strand breaks to initiate Xp11.2 translocation renal cell carcinoma.雌二醇增加拓扑异构酶 IIβ介导的 DNA 链断裂,从而引发 Xp11.2 易位性肾细胞癌。
Cell Commun Signal. 2021 Nov 16;19(1):114. doi: 10.1186/s12964-021-00790-3.
8
Exploring G-quadruplex structure in PRCC-TFE3 fusion oncogene: Plausible use as anti cancer therapy for translocation Renal cell carcinoma (tRCC).探索 PRCC-TFE3 融合癌基因中的 G-四链体结构:作为治疗易位性肾细胞癌(tRCC)的抗癌疗法的可能性。
J Biotechnol. 2024 Jul 10;390:39-49. doi: 10.1016/j.jbiotec.2024.05.004. Epub 2024 May 11.
9
Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.术前中性粒细胞与淋巴细胞比值可预测Xp11.2易位/TFE3肾细胞癌患者的手术结果。
BMC Urol. 2018 Jun 11;18(1):60. doi: 10.1186/s12894-018-0374-z.
10
Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.新设计的断裂分离和ASPL-TFE3双融合荧光原位杂交检测法在诊断Xp11.2易位性肾细胞癌和ASPL-TFE3肾细胞癌中具有应用价值:一篇遵循STARD规范的文章
Medicine (Baltimore). 2015 May;94(19):e873. doi: 10.1097/MD.0000000000000873.

引用本文的文献

1
Emerging roles of exosomes in the diagnosis and treatment of kidney diseases.外泌体在肾脏疾病诊断和治疗中的新作用。
Front Pharmacol. 2025 Apr 16;16:1525314. doi: 10.3389/fphar.2025.1525314. eCollection 2025.
2
Exosomal Biomarkers: A Comprehensive Overview of Diagnostic and Prognostic Applications in Malignant and Non-Malignant Disorders.外泌体生物标志物:恶性和非恶性疾病诊断及预后应用的全面概述
Biomolecules. 2025 Apr 15;15(4):587. doi: 10.3390/biom15040587.
3
HIF1α Plays a Crucial Role in the Development of TFE3-Rearranged Renal Cell Carcinoma by Orchestrating a Metabolic Shift Toward Fatty Acid Synthesis.

本文引用的文献

1
Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers.遗传性肾癌中的缺氧、血管生成和代谢。
J Clin Invest. 2019 Feb 1;129(2):442-451. doi: 10.1172/JCI120855. Epub 2019 Jan 7.
2
The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.经聚焦遗传学检测后,在儿童肿瘤学组(COG)方案 AREN03B2 上登记的小儿和青年肾细胞癌的分类。
Cancer. 2018 Aug;124(16):3381-3389. doi: 10.1002/cncr.31578. Epub 2018 Jun 15.
3
Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients.
缺氧诱导因子1α通过调控向脂肪酸合成的代谢转变,在TFE3重排肾细胞癌的发展中起关键作用。
Genes Cells. 2025 Jan;30(1):e13195. doi: 10.1111/gtc.13195.
4
Deficiency Enhances Tumor Progression via ERBB3 Signaling in -Rearranged Renal Cell Carcinoma.在染色体易位型肾细胞癌中,缺陷通过ERBB3信号通路促进肿瘤进展。
Curr Issues Mol Biol. 2024 Dec 2;46(12):13675-13695. doi: 10.3390/cimb46120817.
5
Frontier role of extracellular vesicles in kidney disease.细胞外囊泡在肾脏疾病中的前沿作用。
J Nanobiotechnology. 2024 Sep 20;22(1):583. doi: 10.1186/s12951-024-02852-3.
6
Exosomes as novel tools for renal cell carcinoma therapy, diagnosis, and prognosis.外泌体作为肾细胞癌治疗、诊断和预后的新型工具。
Heliyon. 2024 Jun 13;10(12):e32875. doi: 10.1016/j.heliyon.2024.e32875. eCollection 2024 Jun 30.
7
Landscape analysis of alternative splicing in kidney renal clear cell carcinoma and their clinical significance.肾脏透明细胞癌中可变剪接的景观分析及其临床意义。
Aging (Albany NY). 2024 Jun 10;16(11):10016-10032. doi: 10.18632/aging.205915.
8
Kidney Cancer and Potential Use of Urinary Extracellular Vesicles.肾癌与尿细胞外囊泡的潜在用途
Oncol Rev. 2024 May 23;18:1410450. doi: 10.3389/or.2024.1410450. eCollection 2024.
9
The role of natural products versus miRNA in renal cell carcinoma: implications for disease mechanisms and diagnostic markers.天然产物与 miRNA 在肾细胞癌中的作用:对疾病机制和诊断标志物的启示。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):6417-6437. doi: 10.1007/s00210-024-03121-8. Epub 2024 May 1.
10
Biomarkers in renal cell carcinoma and their targeted therapies: a review.肾细胞癌中的生物标志物及其靶向治疗:综述
Explor Target Antitumor Ther. 2023;4(5):941-961. doi: 10.37349/etat.2023.00175. Epub 2023 Oct 25.
小细胞肺癌和非小细胞肺癌患者血液中的外泌体微小RNA种类
Oncotarget. 2018 Apr 13;9(28):19793-19806. doi: 10.18632/oncotarget.24857.
4
Tumor suppressor miR-211-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma.肿瘤抑制因子miR-211-5p与肾细胞癌的细胞迁移、增殖和凋亡相关。
Exp Ther Med. 2018 Apr;15(4):4019-4028. doi: 10.3892/etm.2018.5908. Epub 2018 Feb 28.
5
Time-dependent change in relapse sites of renal cell carcinoma after curative surgery.根治性手术后肾癌复发部位的时间依赖性变化。
Clin Exp Metastasis. 2018 Feb;35(1-2):69-75. doi: 10.1007/s10585-018-9883-0. Epub 2018 Mar 7.
6
TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma.肿瘤微环境介导的 TET2 依赖性 IL-6 诱导促进骨肉瘤的肿瘤转移。
Oncogene. 2018 May;37(22):2903-2920. doi: 10.1038/s41388-018-0160-0. Epub 2018 Mar 8.
7
HMGA2 facilitates epithelial-mesenchymal transition in renal cell carcinoma by regulating the TGF-β/Smad2 signaling pathway.HMGA2 通过调节 TGF-β/Smad2 信号通路促进肾细胞癌的上皮-间充质转化。
Oncol Rep. 2018 Jan;39(1):101-108. doi: 10.3892/or.2017.6091. Epub 2017 Nov 10.
8
Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification.肾细胞肿瘤:了解其分子病理流行病学和 2016 年 WHO 分类。
Int J Mol Sci. 2017 Oct 20;18(10):2195. doi: 10.3390/ijms18102195.
9
MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma.MYC 激活与 Vhl 和 Ink4a/Arf 缺失协同作用诱导肾透明细胞癌。
Nat Commun. 2017 Jun 8;8:15770. doi: 10.1038/ncomms15770.
10
MicroRNA expression profiling of Xp11 renal cell carcinoma.Xp11肾细胞癌的微小RNA表达谱分析
Hum Pathol. 2017 Sep;67:18-29. doi: 10.1016/j.humpath.2017.03.011. Epub 2017 Apr 12.